Literature DB >> 17639217

Planning to improve global health: the next decade of tuberculosis control.

Dermot Maher1, Chris Dye, Katherine Floyd, Andrea Pantoja, Knut Lonnroth, Alasdair Reid, Eva Nathanson, Thad Pennas, Uli Fruth, Jane Cunningham, Heather Ignatius, Mario C Raviglione, Irene Koek, Marcos Espinal.   

Abstract

The Global Plan to Stop TB 2006-2015 is a road map for policy-makers and managers of national programmes. It sets out the key actions needed to achieve the targets of the Millennium Development Goals relating to tuberculosis (TB): to halve the prevalence and deaths by 2015 relative to 1990 levels and to save 14 million lives. Developed by a broad coalition of partners, the plan presents a model approach combining interventions that can feasibly be supplied on the ground. The main areas of activity set out in the plan are: scaling up interventions to control tuberculosis; promoting the research and development of improved diagnostics, drugs and vaccines; and engaging in related activities for advocacy, communications and social mobilization. Scenarios for the planning process were developed; these looked at issues both globally and in seven epidemiological regions. The scenarios made ambitious but realistic assumptions about the pace of scale-up and implementation coverage of the activities. A mathematical model was used to estimate the impact of scaling up current interventions based on data from studies of tuberculosis biology and from experience with tuberculosis control in diverse settings. The estimated costs of the activities set out in the Global Plan were based on implementing interventions and researching and developing drugs, diagnostics and vaccines; these costs were US$ 56 billion over 10 years. When translated into cost per disability adjusted life year averted, these costs compare favourably with those of other public health interventions. This approach to planning for global tuberculosis control is a valuable example of developing plans to improve global health that has relevance for other health issues.

Entities:  

Mesh:

Year:  2007        PMID: 17639217      PMCID: PMC2636650          DOI: 10.2471/blt.06.037820

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  12 in total

Review 1.  Global Partnership to Stop TB: a model of an effective public health partnership.

Authors:  J Kumaresan; P Heitkamp; I Smith; N Billo
Journal:  Int J Tuberc Lung Dis       Date:  2004-01       Impact factor: 2.373

2.  Whither onchocerciasis control in Africa?

Authors:  D R Hopkins; F O Richards; M Katabarwa
Journal:  Am J Trop Med Hyg       Date:  2005-01       Impact factor: 2.345

3.  The impact of HIV/AIDS on the control of tuberculosis in India.

Authors:  B G Williams; R Granich; L S Chauhan; N S Dharmshaktu; C Dye
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-23       Impact factor: 11.205

Review 4.  Targets for global tuberculosis control.

Authors:  C Dye; D Maher; D Weil; M Espinal; M Raviglione
Journal:  Int J Tuberc Lung Dis       Date:  2006-04       Impact factor: 2.373

5.  Medicine. A portfolio model of drug development for tuberculosis.

Authors:  Seth W Glickman; Emma B Rasiel; Carol Dukes Hamilton; Arsen Kubataev; Kevin A Schulman
Journal:  Science       Date:  2006-03-03       Impact factor: 47.728

6.  WHO's new Stop TB Strategy.

Authors:  Mario C Raviglione; Mukund W Uplekar
Journal:  Lancet       Date:  2006-03-18       Impact factor: 79.321

7.  The end of poverty: economic possibilities for our time.

Authors:  Jeffrey Sachs
Journal:  Eur J Dent Educ       Date:  2008-02       Impact factor: 2.355

8.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

Authors:  Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland
Journal:  Lancet       Date:  2006-11-04       Impact factor: 79.321

9.  Tuberculosis epidemics driven by HIV: is prevention better than cure?

Authors:  Christine S M Currie; Brian G Williams; Russell C H Cheng; Christopher Dye
Journal:  AIDS       Date:  2003-11-21       Impact factor: 4.177

10.  The development and impact of tuberculosis vaccines.

Authors:  Douglas Young; Christopher Dye
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

View more
  14 in total

Review 1.  Notch system in the linkage of innate and adaptive immunity.

Authors:  Toshihiro Ito; Judith M Connett; Steven L Kunkel; Akihiro Matsukawa
Journal:  J Leukoc Biol       Date:  2012-03-29       Impact factor: 4.962

2.  Tuberculosis and its future management.

Authors:  John C Moore-Gillon
Journal:  Thorax       Date:  2007-12       Impact factor: 9.139

3.  Financial resources required for tuberculosis control to achieve global targets set for 2015.

Authors:  Katherine Floyd; Andrea Pantoja
Journal:  Bull World Health Organ       Date:  2008-07       Impact factor: 9.408

4.  Global community perception of 'surgical care' as a public health issue: a cross sectional survey.

Authors:  Nurhayati Lubis; Meena Nathan Cherian; Chinmayee Venkatraman; Fiemu E Nwariaku
Journal:  BMC Public Health       Date:  2021-05-20       Impact factor: 3.295

Review 5.  Epidemiology and challenges to the elimination of global tuberculosis.

Authors:  Mandeep S Jassal; William R Bishai
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

6.  Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis.

Authors:  Diane Ordway; Marcela Henao-Tamayo; Crystal Shanley; Erin E Smith; Gopinath Palanisamy; Baolin Wang; Randall J Basaraba; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2008-05-28

7.  A systematic assessment of the concept and practice of public-private mix for tuberculosis care and control.

Authors:  Rasmus Malmborg; Gillian Mann; S Bertel Squire
Journal:  Int J Equity Health       Date:  2011-11-10

8.  Correlations between drug resistance of Beijing/W lineage clinical isolates of Mycobacterium tuberculosis and sublineages: a 2009-2013 prospective study in Xinjiang province, China.

Authors:  Xian-hua Wang; Ai-guo Ma; Xiu-xia Han; Xiao-ming Gu; Li-ping Fu; Peng-gang Li; Fen-yu Li; Qiu-zhen Wang; Hui Liang; Abudu Katar; Li-jie Wang
Journal:  Med Sci Monit       Date:  2015-05-07

9.  IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia.

Authors:  Helena del Corral; Sara C París; Nancy D Marín; Diana M Marín; Lucelly López; Hanna M Henao; Teresita Martínez; Liliana Villa; Luis F Barrera; Blanca L Ortiz; María E Ramírez; Carlos J Montes; María C Oquendo; Lisandra M Arango; Felipe Riaño; Carlos Aguirre; Alberto Bustamante; John T Belisle; Karen Dobos; Gloria I Mejía; Margarita R Giraldo; Patrick J Brennan; Jaime Robledo; María P Arbeláez; Carlos A Rojas; Luis F García
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

10.  Relatively low level of antigen-specific monocytes detected in blood from untreated tuberculosis patients using CD4+ T-cell receptor tetramers.

Authors:  Yuhong Huang; Yan Huang; Yimin Fang; Juan Wang; Yan Li; Nan Wang; Jianbo Zhang; Ming Gao; Lirong Huang; Fangfang Yang; Cong Wang; Shuxian Lin; Yanan Yao; Liangliang Ren; Yi Chen; Xuanjing Du; Dan Xie; Rongshun Wu; Kouxing Zhang; Lifang Jiang; Xinbing Yu; Xiaomin Lai
Journal:  PLoS Pathog       Date:  2012-11-29       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.